Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 13;25(1):142.
doi: 10.1186/s13058-023-01726-0.

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning

Affiliations

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning

Witali Aswolinskiy et al. Breast Cancer Res. .

Abstract

Background: Invasive breast cancer patients are increasingly being treated with neoadjuvant chemotherapy; however, only a fraction of the patients respond to it completely. To prevent overtreatment, there is an urgent need for biomarkers to predict treatment response before administering the therapy.

Methods: In this retrospective study, we developed hypothesis-driven interpretable biomarkers based on deep learning, to predict the pathological complete response (pCR, i.e., the absence of tumor cells in the surgical resection specimens) to neoadjuvant chemotherapy solely using digital pathology H&E images of pre-treatment breast biopsies. Our approach consists of two steps: First, we use deep learning to characterize aspects of the tumor micro-environment by detecting mitoses and segmenting tissue into several morphology compartments including tumor, lymphocytes and stroma. Second, we derive computational biomarkers from the segmentation and detection output to encode slide-level relationships of components of the tumor microenvironment, such as tumor and mitoses, stroma, and tumor infiltrating lymphocytes (TILs).

Results: We developed and evaluated our method on slides from n = 721 patients from three European medical centers with triple-negative and Luminal B breast cancers and performed external independent validation on n = 126 patients from a public dataset. We report the predictive value of the investigated biomarkers for predicting pCR with areas under the receiver operating characteristic curve between 0.66 and 0.88 across the tested cohorts.

Conclusion: The proposed computational biomarkers predict pCR, but will require more evaluation and finetuning for clinical application. Our results further corroborate the potential role of deep learning to automate TILs quantification, and their predictive value in breast cancer neoadjuvant treatment planning, along with automated mitoses quantification. We made our method publicly available to extract segmentation-based biomarkers for research purposes.

Keywords: Computational biomarker; Neoadjuvant chemotherapy; Pathological complete response.

PubMed Disclaimer

Conflict of interest statement

FC was Chair of the Scientific and Medical Advisory Board of TRIBVN Healthcare, France, and received advisory board fees from TRIBVN Healthcare, France, in the last five years. He is shareholder of Aiosyn BV, the Netherlands. MB is medical advisor at Aiosyn BV. All other authors declare no conflict of interest. JvdL was a member of the advisory boards of Philips, the Netherlands and ContextVision, Sweden, and received research funding from Philips, the Netherlands, ContextVision, Sweden, and Sectra, Sweden in the last five years. He is chief scientific officer (CSO) and shareholder of Aiosyn BV, the Netherlands.

Figures

Fig. 1
Fig. 1
Method overview: (1) Segment slides into different tissue types and detect mitoses. (2) Compute biomarkers from the segmentation prediction of tumor, stroma and lymphocytes and detected mitoses within tumor regions. LTR: lymphocyte-tumor ratio, cTILs: computational tumor infiltrating lymphocytes score, ITR: inflamed tumor ratio (proportion of tumor close to lymphocytes), MTR: mitoses-tumor ratio
Fig. 2
Fig. 2
Biomarker development and evaluation data: visualization of the data split per type (TNBC, Luminal B), center (NKI, RUMC+SCDC, IMPRESS) and data subset (development, evaluation), starting from the exclusion of cases due to quality (in gray) and for training of the segmentation model (in blue, part of devsegtrain) to the definition of the development (in green, devbm) and evaluation (in yellow, valint) datasets. Shown is also the additional IMPRESS [24] evaluation data (in orange, valext). Not included is the additional data for segmentation model training
Fig. 3
Fig. 3
Segmentation and detection examples. On the top left is an example from a test slide with the segmentation overlay on the right. Predicted tumor is hued blue, necrosis magenta, lymphocytes purple, stroma orange and the rest green. The drawn polygons are the tissue annotations (red: Lymphocytes, black: Tumor). The slides were annotated using ASAP(https://github.com/computationalpathologygroup/ASAP). On the bottom are examples of kept (top) and filtered out (bottom) mitoses detections
Fig. 4
Fig. 4
Visualization of the cTILs bulk (top) and the ITR radius (bottom) via blue polygons. In the overlays (right), tumor is hued blue, stroma orange, lymphocytes purple, necrosis magenta, fatty tissue yellow and the rest green
Fig. 5
Fig. 5
Receiver Operating Characteristic (ROC) curves for predicting pCR on the evaluation sets

References

    1. Masood S. Neoadjuvant chemotherapy in breast cancers. Womens Health. 2016;12(5):480–491. - PMC - PubMed
    1. Asaoka M, Gandhi S, Ishikawa T, Takabe K. Neoadjuvant chemotherapy for breast cancer: past, present, and future. Breast Cancer: Basic Clin Res. 2020;14:1178223420980377. - PMC - PubMed
    1. Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carbognin L, Michelotti A, Iezzi L, et al. Neoadjuvant chemotherapy in triple-negative breast cancer: a multicentric retrospective observational study in real-life setting. J Cell Physiol. 2018;233(3):2313–2323. doi: 10.1002/jcp.26103. - DOI - PubMed
    1. Bonnefoi H, Litière S, Piccart M, MacGrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan C, et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the eortc 10994/big 1–00 phase iii trial. Ann Oncol. 2014;25(6):1128–1136. doi: 10.1093/annonc/mdu118. - DOI - PMC - PubMed
    1. Denkert C, Loibl S, Noske A, Roller M, Muller B, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–113. doi: 10.1200/JCO.2009.23.7370. - DOI - PubMed

Publication types